A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Pemigatinib (Primary)
- Indications Adenocarcinoma; Astrocytoma; Bladder cancer; Cervical cancer; Cholangiocarcinoma; CNS cancer; Endometrial cancer; Glioblastoma; Glioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- Acronyms FIGHT-207
- Sponsors Incyte Corporation
Most Recent Events
- 01 Jun 2024 Results assessing safety and efficacy of Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations published in the Nature Medicine
- 27 Apr 2023 Status changed from discontinued to active, no longer recruiting.
- 27 Apr 2023 Results assessing the activity of pemigatinib in the subset of patients with previously treated CNS tumors, presented at the 75th Annual Meeting of the American Academy of Neurology 2023